Pharma large Novo Nordisk introduced that it’s collaborating with WeightWatchers to supply Wegovy by way of NovoCare Pharmacy, efficient July 1.
By way of the partnership, WeightWatchers’ telehealth program, built-in into NovoCare Pharmacy, will allow new uninsured or self-paying sufferers to entry Wegovy for $299 per 30 days for one month at any dose and subsequently $499 per 30 days after. The supply is legitimate from July 1 by way of July 31.
Novo Nordisk says the provides will assist sufferers “beforehand prescribed unapproved ‘semaglutide’ begin on FDA-approved Wegovy.”
WeightWatchers will dispense Wegovy by way of CenterWell Pharmacy, which handles prescription success and supply for NovoCare Pharmacy.
Novo Nordisk mentioned the supply will likely be efficient by way of every of its telehealth companions: Ro, LifeMD and now WeightWatchers. The identical deal will even be accessible to sufferers immediately by way of NovoCare Pharmacy.
“We perceive that how individuals select to obtain care is altering, and in response to that, we’re collaborating with WeightWatchers to ship extra accessible care to these residing with power weight problems,” Dave Moore, govt vp of U.S. operations of Novo Nordisk, mentioned in an announcement.
“WeightWatchers has spent over six many years constructing a science-backed strategy to weight administration, and we see sturdy synergy in our shared dedication to bettering long-term well being outcomes. We now have additionally been very inspired with our current Ro and LifeMD collaborations. We’ll proceed to pursue and construct on agreements with corporations that share our values and refine initiatives that assist enhance entry to our FDA-approved medicines for sufferers.”
THE LARGER TREND
Earlier this week, Novo Nordisk introduced it was terminating its contract with Hims & Hers, which was introduced lower than two months in the past, alleging the direct-to-consumer digital care firm is violating federal legislation by promoting compounded variations of the drug at scale underneath the pretense of “personalization.”
Novo Nordisk additionally accused Hims & Hers of utilizing deceptive advertising and marketing practices, which it claims put affected person security in danger.
Hims & Hers responded to the allegations, writing on LinkedIn, “It is a transfer by a pharmaceutical large to guard its personal pursuits by difficult lawful, customized compounded care. Much more troubling is the hassle to conflate lawful compounders with dangerous actors. That is deceptive and dangerous, particularly for sufferers with advanced wants.”
The corporate’s CEO, Andrew Dedum, wrote on X, “In current weeks, Novo Nordisk’s industrial group more and more pressured us to manage scientific requirements and steer sufferers to Wegovy no matter whether or not it was clinically finest for sufferers. We refuse to be strong-armed by any pharmaceutical firm’s anticompetitive calls for that infringe on the impartial decision-making of suppliers and restrict affected person alternative.”
Novo Nordisk additionally companions with direct-to-consumer digital care firm Ro and publicly traded telemedicine firm LifeMD to promote its weight-loss drug by way of the telehealth suppliers to cash-paying purchasers.
In an announcement asserting the WeightWatchers partnership, the pharma large mentioned, “Ro and LifeMD collaborations proceed based mostly on their dedication to offering protected and efficient medical therapy for sufferers residing with power ailments; dialogue with different corporations ongoing.”
Leave a Reply